Shares of Vericel Co. (NASDAQ:VCEL - Get Free Report) were up 5.3% during mid-day trading on Tuesday . The company traded as high as $59.44 and last traded at $59.44. Approximately 106,520 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 424,401 shares. The stock had previously closed at $56.46.
Wall Street Analysts Forecast Growth
Several research firms have commented on VCEL. StockNews.com cut shares of Vericel from a "hold" rating to a "sell" rating in a research report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Friday, November 8th. Canaccord Genuity Group restated a "buy" rating and issued a $60.00 price objective on shares of Vericel in a research note on Tuesday, November 19th. TD Cowen raised their target price on Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, August 27th. Finally, Stephens raised shares of Vericel to a "strong-buy" rating in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vericel has a consensus rating of "Moderate Buy" and a consensus price target of $59.71.
View Our Latest Analysis on Vericel
Vericel Trading Up 0.4 %
The firm has a fifty day moving average of $50.84 and a two-hundred day moving average of $48.06. The company has a market cap of $2.80 billion, a PE ratio of 944.83 and a beta of 1.71.
Vericel (NASDAQ:VCEL - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Sell-side analysts expect that Vericel Co. will post 0.13 EPS for the current fiscal year.
Insider Buying and Selling at Vericel
In related news, Director Paul K. Wotton sold 2,600 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total transaction of $152,672.00. Following the sale, the director now owns 27,402 shares of the company's stock, valued at approximately $1,609,045.44. This represents a 8.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at $443,850. This represents a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,266 shares of company stock valued at $2,090,636 in the last 90 days. 5.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in Vericel by 214.0% in the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock worth $24,837,000 after acquiring an additional 400,667 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Vericel in the third quarter worth approximately $563,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Vericel by 4.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company's stock valued at $45,590,000 after purchasing an additional 47,108 shares during the last quarter. Scholtz & Company LLC bought a new stake in Vericel during the second quarter valued at approximately $1,357,000. Finally, Premier Fund Managers Ltd purchased a new position in Vericel in the 3rd quarter worth approximately $781,000.
Vericel Company Profile
(
Get Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Articles
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
